Table 2.

Characteristics of included studies.

Study	Region	No. of patients	Study period	Follow-up (median, months)	Age (years)	Gender (male/female)	miRNA	Survival
Wszolek, 2011	USA	57	1990–2005	92	66.4 (34–90)	38/19	141, 200	CSS
Yun, 2012	Korea	207	2006–2012	41.3	63.5 ± 12.6	165/42	200	RFS
Ratert, 2013	Germany	40	1998–2009	17	69 (50–92)	32/8	141	OS
Pignot, 2013	France	166	2001–2005	30.5	70 (31–91)	138/28	200	OS, RFS
Wang, 2015	China	114	NA	42.9	70.0 ± 10.1	86/28	141	OS, CSS, RFS
Martínez-Fernández, 2015	Spain	87	2009–2012	28.8	73.0 (49–90)	68/19	200	OS, RFS
Liu, 2018	China	403	NA	41.6	60.1 (34–90)	297/106	141, 200	OS
Wu, 2018	China	76	2002–2006	36.5	NA	57/19	429	OS, RFS

CSS = cancer-specific survival, NA = not available, OS = overall survival, RFS = recurrence-free survival.